LYNPARZA, also known by its generic name olaparib, is a targeted therapy medication used in the treatment of certain types of cancer, including ovarian, breast, pancreatic, and prostate cancers. It belongs to a class of drugs known as PARP inhibitors, which work by interfering with the DNA repair process in cancer cells, causing them to die and thereby slowing the progression of the disease. LYNPARZA is specifically designed for patients who have specific genetic mutations, such as BRCA mutations, making it a form of precision medicine. It is typically administered in pill form, making it an oral medication. Due to its targeted approach, LYNPARZA offers a promising treatment option for patients with these genetic profiles, although it may come with its own set of side effects that patients should discuss with their healthcare provider.